These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 29986353)

  • 41. HIV/hepatitis coinfection in eastern Europe and new pan-European approaches to hepatitis prevention and management.
    Lazarus JV; Shete PB; Eramova I; Merkinaite S; Matic S
    Int J Drug Policy; 2007 Oct; 18(5):426-32. PubMed ID: 17854732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies.
    Richmond JA; Gallagher L; McDonald L; O'Sullivan M; Fitzsimmons C; Pedrana A
    Gastroenterol Nurs; 2020; 43(4):303-309. PubMed ID: 32665524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
    BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. "Towards eliminating viral hepatitis": Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination.
    Lancaster K; Rhodes T; Rance J
    Int J Drug Policy; 2020 Jun; 80():102419. PubMed ID: 30975593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leaving no one behind: Towards equitable global elimination of hepatitis C.
    Dahl EH; Zahid H; Aslam K; Jafri W
    J Glob Health; 2020 Jun; 10(1):010308. PubMed ID: 32257136
    [No Abstract]   [Full Text] [Related]  

  • 46. Achieving hepatitis C elimination in Taiwan-Overcoming barriers by setting feasible strategies.
    Wu GH; Pwu RF; Chen SC
    J Formos Med Assoc; 2018 Dec; 117(12):1044-1045. PubMed ID: 30449458
    [No Abstract]   [Full Text] [Related]  

  • 47. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis G; Razavi H; Hatzakis A
    J Gastroenterol Hepatol; 2017 Feb; 32(2):466-472. PubMed ID: 27403912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements.
    Grebely J; Matthews GV; Lloyd AR; Dore GJ
    Clin Infect Dis; 2013 Oct; 57(7):1014-20. PubMed ID: 23728143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Towards eliminating hepatitis C as a public health threat: different speeds, different needs.
    Matičič M; Buti M
    Euro Surveill; 2024 Jul; 29(30):. PubMed ID: 39056197
    [No Abstract]   [Full Text] [Related]  

  • 50. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH).
    Crespo J; Albillos A; Buti M; Calleja JL; García Samaniego J; Hernández Guerra M; Serrano T; Turnes J; Acín E; Berenguer J; Berenguer M; Colom J; Fernández I; Fernández Rodríguez C; Forns X; García F; Grandados R; Lazarus JV; Molero JM; Molina E; Pérez Escanilla F; Pineda JA; Rodríguez M; Romero M; Roncero C; Saiz de la Hoya P; Sánchez Antolín G
    Rev Esp Enferm Dig; 2019 Nov; 111(11):862-873. PubMed ID: 31657609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
    Scott N; McBryde ES; Thompson A; Doyle JS; Hellard ME
    Gut; 2017 Aug; 66(8):1507-1515. PubMed ID: 27196586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Can hepatitis C virus infection be eradicated in people who inject drugs?
    Grebely J; Dore GJ
    Antiviral Res; 2014 Apr; 104():62-72. PubMed ID: 24468275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups.
    Falla AM; Hofstraat SHI; Duffell E; Hahné SJM; Tavoschi L; Veldhuijzen IK
    BMC Infect Dis; 2018 Feb; 18(1):79. PubMed ID: 29433454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is elimination of hepatitis C from the UK by 2030 a realistic goal?
    Gelson W; Alexander G
    Br Med Bull; 2017 Sep; 123(1):59-67. PubMed ID: 28605444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Remaining challenges in HCV elimination.
    Capraru C; Feld JJ
    J Hepatol; 2021 Apr; 74(4):964-965. PubMed ID: 33589319
    [No Abstract]   [Full Text] [Related]  

  • 57. Excellence in viral hepatitis elimination - Lessons from Georgia.
    Averhoff F; Lazarus JV; Sergeenko D; Colombo M; Gamkrelidze A; Tsertsvadze T; Butsashvili M; Metreveli D; Sharvadze L; Hellard M; Gnes S; Gabunia T; Nasrullah M
    J Hepatol; 2019 Oct; 71(4):645-647. PubMed ID: 31356831
    [No Abstract]   [Full Text] [Related]  

  • 58. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Micro-elimination - A path to global elimination of hepatitis C.
    Lazarus JV; Wiktor S; Colombo M; Thursz M;
    J Hepatol; 2017 Oct; 67(4):665-666. PubMed ID: 28760329
    [No Abstract]   [Full Text] [Related]  

  • 60. Care and treatment of hepatitis C among Aboriginal people in New South Wales, Australia: implications for the implementation of new treatments.
    Treloar C; Jackson C; Gray R; Newland J; Wilson H; Saunders V; Johnson P; Brener L
    Ethn Health; 2016; 21(1):39-57. PubMed ID: 25665723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.